TORONTO, July 30, 2018 /CNW/ – Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC; Frankfurt 3CM), a leading business technology company in the cannabis space, is pleased to announce that its premiere cannabis education platform, Cannvas.me will be offered through a physical device in medical and related clinics. Patients and medical professionals will have access to a low cost, application specific, hand held device to learn about the benefits of health and wellness through cannabis and to access information specific to their needs.
“Through discussions with medical professionals, the need for education at the point of treatment was clearly evident,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “Our solution is to have a physical device specific to medical cannabis education and information in medical and related clinics. Our goal is to quickly expand our offering to every clinic across Canadaand friendly jurisdictions around the world. Throughout the development of Cannvas.me this has been taken into consideration while rolling out the landscape of integration with potential clinic partners. With the Cannvas.me platform launch quickly approaching, we are in a position to accelerate those conversations and convert them into integrated educational delivery partners.”
Through widespread medical clinic integration, medical patients will be able to access the Cannvas.me education platform at the source of their treatment: medical and related clinics. Access to trusted information is important for both the patient and the prescribing medical professional. Due to the lack of available information, medical professionals have been reluctant to prescribe cannabis in its many forms. By providing information at the source of treatment, it will give the patient peace of mind by looking at all alternatives and doctors the confidence to write the suitable prescriptions for the specific ailments.
Cannvas is currently in the final stages of partnership integration protocols and revenue share guidelines, which would be utilized with our potential partners. Cannvas has set aggressive expansion targets which we feel are achievable through current discussions with existing networks worldwide.
Cannvas also announces that it has issued an aggregate of 3,500,000 common shares (the “Shares”) of the Company at a deemed value of $0.35 per Share to Shawn Moniz, CEO and a director of the Company, and Steve Loutskou, COO and a director of the Company, pursuant to the achievement of certain milestones and in accordance with their respective consulting agreements.
Cannvas.me is an innovative and unbiased online health sciences educational platform where patients can take an active role in defining the path of control of their health and wellness through the use of cannabis. It is a scalable and comprehensive solution for the global cannabis community offering interactive tools and physician-backed content. It takes an innovative approach to place cannabis education at the forefront by bringing design, creativity, data aggregation and global connectivity to new heights. Through subsidiaries Cannvas Creative, Cannvas Data and Cannvas Connect; Cannvas.me will feature innovative tools such as educational learning modules in its Cannvas University, an interactive Cannvas Strain Matcher that educates audiences with specific ailments, and Cannvas Culinary, for those wishing to learn about the culinary approach to treatments.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
SOURCE Cannvas MedTech Inc.